NCT00794859Unknown2 期
Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 54
- 试验地点
- 2
- 主要终点
- Progression-free survival
研究概览
简要总结
The principal objective of the study is to investigate the effect of sorafenib on progression free survival (time until the cancer begins to grow again,) in patients with malignant mesothelioma who have had prior treatment with chemotherapy. Effectiveness of the drug will also be explored with PET scans before and during treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Malignant pleural or peritoneal mesothelioma previously treated with first line platinum-based chemotherapy (prior pemetrexed not required)
- •Not suitable for radical resection. Prior radical or cytoreductive surgery allowed
- •Age >18 years
- •ECOG performance status 0-2
- •Measurable disease. Lesions must be measured by CT scan or MRI according to modified RECIST (Appendix B)
- •Life expectancy of at least 12 weeks
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:
- •haemoglobin ≥ 9.0 g/dL
- •neutrophil count ≥ 1.5 x109/L
- •platelet count ≥ 100 x109/L
- •total bilirubin ≤ 1.5 x upper limit of normal
- •ALT and AST ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for *alkaline phosphatase ≤ 4 x upper limit of normal
- •PT-INR (international normalized ratio of PT) / PTT ≤1.5 x upper limit of normal
- •Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures.
排除标准
- •History of cardiac disease: congestive heart failure > NYHA (New York Heart Association) class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted); or uncontrolled hypertension (defined as systolic blood pressure >150mmHg or diastolic pressure >90mmHg despite optimal medical management)
- •Impaired immunity or chronic infection including history of HIV (human immunodeficiency virus) infection or chronic hepatitis B or C
- •Active clinically serious infections (> grade 2 NCI-CTCAE version 3.0)
- •Seizure disorder requiring medication (such as steroids or anti-epileptics)
- •Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis
- •History of organ allograft
- •Evidence or history of bleeding diathesis or coagulopathy;
- •Renal dialysis
- •Cancer other than mesothelioma within 5 years prior to start of study treatment EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumours [Ta (noninvasive tumour), Tis (carcinoma in situ) & T1 (tumour invading lamina propria)]
- •Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
- •Pulmonary haemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug
- •Any other haemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug
- •Serious, non-healing wound, ulcer, or bone fracture
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Known or suspected allergy to the investigational agent or any agent given in association with this trial
- •Any condition that is unstable or could jeopardise the safety of the patient and their compliance in the study
- •Patients unable to swallow oral medications
- •Any malabsorption condition.
- •Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for malignant mesothelioma, other than first line platinum-based combination chemotherapy
- •Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section)
- •Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug (bronchoscopy is allowed)
- •Granulocyte colony stimulating factor (GCSF) or granulocyte macrophage colony stimulating factor (GMCSF), within 3 weeks of study entry
- •Therapeutic anticoagulation with vitamin K antagonists such as warfarin, or with heparins or heparinoids. Low dose warfarin (1 mg po OD) is permitted if the INR (international normalized ratio) is < 1.
- •Low-dose aspirin is permitted (≤ 81 mg daily)
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry.
结局指标
主要结局
Progression-free survival
时间窗: 24 weeks
次要结局
- Response rate as assessed with CT scan(2 months)
- Overall survival(Median)
- Change in FDG-PET avidity(8 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy - SMSMalignant MesotheliomaMedDRA version: 13.1Level: PTClassification code 10027407Term: Mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-005091-13-GBGuy's & St Thomas' NHS Foundation Trust55
已完成
2 期
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.Epithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous MesotheliomaStage IA Malignant MesotheliomaStage IB Malignant MesotheliomaStage II Malignant MesotheliomaStage III Malignant MesotheliomaStage IV Malignant MesotheliomaNCT00107432National Cancer Institute (NCI)44
已完成
2 期
Safety and Toxicity Study of Sorafenib in Patients With Kidney CancerCarcinoma, Renal CellNCT00445042The Methodist Hospital Research Institute71
已完成
2 期
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction CancerGastroesophageal Junction CancerEsophageal CancerNCT00917462Memorial Sloan Kettering Cancer Center35
已完成
2 期
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or BevacizumabKidney CancerNCT00866320Case Comprehensive Cancer Center49